Disease/Infection News

RSS

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12).

15 Apr 2016

Interdisciplinary researchers to explore ethical issues of pregnant women during Zika crisis

The emerging Zika virus epidemic is bringing to light a longstanding ethical challenge in medical research: the inclusion of pregnant women. With new funding from the Wellcome Trust, an interdisciplinary team of scholars will focus on issues of ethics and research in pregnancy and women of reproductive age, beginning with the current Zika context and later expanding to general public health research.

15 Apr 2016

New research in SIV-exposed monkeys provides insights for development of HIV prevention strategies

New research in monkeys exposed to SIV, the monkey equivalent of HIV, suggests that the virus spreads rapidly in the body and triggers early host responses that suppress antiviral immunity, thus promoting viral replication.

15 Apr 2016

Kevin Hollinrake MP, ANTRUK CEO comment on Chancellor George Osborne's IMF speech on antibiotic resistance

Chancellor George Osborne will today warn that resistance to antibiotics will become an “even greater threat to mankind than cancer” without global action. His comments will be presented in a speech at the International Monetary Fund (IMF) meeting in Washington today, 14th April 2016.

15 Apr 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

15 Apr 2016

Researchers develop novel method to store microfluidic devices for CD4 T cell testing

Providing vital health care services to people in developing countries without reliable electricity, refrigeration and state-of-the-art medical equipment poses a number of challenges. Inspired by pregnancy tests, researchers from Florida Atlantic University, Stanford University, and Baskent University in Turkey, have developed a novel method to store microfluidic devices for CD4 T cell testing in extreme weather conditions for up to six months without refrigeration.

14 Apr 2016

Deadly ‘Crypto’ pathogen lures US researcher to UQ

Cryptococcus is so forsaken by research that it doesn’t even make the neglected diseases list – but the deadly fungal pathogen has lured an American scientist all the way to The University of Queensland.

14 Apr 2016

Tackling superbugs with antibiotic resistance breakers: an interview with Professor Colin Garner, Chief Executive, Antibiotic Research UK

Superbugs – or to give them their correct name, antibiotic resistant bacteria – arise on repeated exposure to antibiotics. In any population of bacteria there will be a few that are antibiotic resistant (approximately 1 in 100 million bacteria). If these bacteria are allowed to grow and multiply, an antibiotic resistant infection results.

13 Apr 2016

Coordinated efforts could prevent spread of CRE infection in health care facilities

A simulation of how the so-called "superbug" carbapenem-resistant Enterobacteriaceae (CRE) might spread among health care facilities found that coordinated efforts prevented more than 75 percent of the often-severe infections that would have otherwise occurred over a five-year period.

13 Apr 2016

Hepatitis C treatment can be provided safely, effectively within community-based setting

A new study, presented today, demonstrates treatment for Hepatitis C can be provided safely and effectively within a community-based and non-specialist setting. This illustrates the potential for alternative providers to ease pressure on currently overburdened specialists. The study, sponsored by the National Institutes of Health, was presented at The International Liver Congress 2016 in Barcelona, Spain.

13 Apr 2016

UC San Diego receives NIH grant to establish interdisciplinary center to combat antibiotic resistance

Researchers at University of California, San Diego School of Medicine have received a five-year, $9.5-million award from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health to establish an interdisciplinary center to define the systems biology of antibiotic resistance. The program will be led by Bernhard Palsson, PhD, Distinguished Professor of Bioengineering and Pediatrics, and Victor Nizet, MD, professor of pediatrics and pharmacy.

13 Apr 2016

Spread of STIs, peer pressure may have transformed prehistoric humans to monogamists

Prehistoric humans may have developed social norms that favour monogamy and punish polygamy thanks to the presence of sexually transmitted infections (STIs) and peer pressure, according to new research from the University of Waterloo in Canada.

13 Apr 2016

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness.

13 Apr 2016

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV).

13 Apr 2016

Prime boost approach can increase possibility of combined HCV and HIV vaccination

A combined vaccination against Hepatitis C virus (HCV) and HIV moved a step closer, with the results of a study presented at The International Liver Congress 2016 in Barcelona, Spain today.

13 Apr 2016

Tips to help treat corns and calluses

Ever wonder what causes corns and calluses? According to dermatologists from the American Academy of Dermatology, these hard, thickened areas of skin form as a result of friction or pressure on the skin. In fact, they say, corns and calluses develop naturally to help protect the skin underneath them.

13 Apr 2016

Cary Institute gets $5 million grant to support study on Lyme disease reduction

The Steven & Alexandra Cohen Foundation has awarded a $5 million dollar leadership grant to the Cary Institute of Ecosystem Studies to support a scientific study, being done in partnership with Bard College, that seeks to reduce Lyme disease in neighborhoods.

13 Apr 2016

New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients

AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.

13 Apr 2016

Researchers observe increase in antibiotic resistance genes

Around the world, antibiotic use and resistance is increasing while the discovery of new antibiotics has nearly halted.

13 Apr 2016

Bacteroidia pilins prevalent in human gut and mouth form new type of pili to cling to hosts

Many bacteria interact with their environment through hair-like structures known as pili, which attach to and help mediate infection of host organisms, among other things. Now a U.S.-Japanese research team, including scientists from the Department of Energy's SLAC National Accelerator Laboratory, has discovered that certain bacteria prevalent in the human gut and mouth assemble their pili in a previously unknown way - information that could potentially open up new ways of fighting infection.

12 Apr 2016

Disease/Infection News

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

Interdisciplinary researchers to explore ethical issues of pregnant women during Zika crisis

New research in SIV-exposed monkeys provides insights for development of HIV prevention strategies

Kevin Hollinrake MP, ANTRUK CEO comment on Chancellor George Osborne's IMF speech on antibiotic resistance

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

Researchers develop novel method to store microfluidic devices for CD4 T cell testing

Deadly ‘Crypto’ pathogen lures US researcher to UQ

Tackling superbugs with antibiotic resistance breakers: an interview with Professor Colin Garner, Chief Executive, Antibiotic Research UK

Coordinated efforts could prevent spread of CRE infection in health care facilities

Hepatitis C treatment can be provided safely, effectively within community-based setting

UC San Diego receives NIH grant to establish interdisciplinary center to combat antibiotic resistance

Spread of STIs, peer pressure may have transformed prehistoric humans to monogamists

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Prime boost approach can increase possibility of combined HCV and HIV vaccination

Tips to help treat corns and calluses

Cary Institute gets $5 million grant to support study on Lyme disease reduction

New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients

Researchers observe increase in antibiotic resistance genes

Bacteroidia pilins prevalent in human gut and mouth form new type of pili to cling to hosts

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News